Welcome to Grünenthal's Press Archives
16 May 2013
Last weekend the U.S. Food and Drug Administration (FDA) has denied a Citizen Petition filed by Endo Pharmaceuticals. Amongst others Endo requested the FDA to refuse the approval of any abbreviated new drug applications that referenced the non-abuse deterrent version of one of the company's pain drugs and suspend the approvals of generic formulations of these drugs currently on the market.
13 May 2013
Specialist global pharmaceutical company Grünenthal with revenue growth driven by innovative pain brands
Adjusted revenues grow 13 percent in 2012 / Operating EBITA margin improved by 8 percentage points / Revenue proportion of pain products on the market up to 5 years before 2012 approx. 30 percent / Continued high investment in R&D / Two pan-regional in-licensing agreements in Latin America
19 Apr 2013
Grünenthal Highlights Significant R&D Advances in Pain, Inflammation as well as INTAC® Tamper-Resistant Technology at World’s Largest Biotechnology Conference
Aachen (Germany) / Chicago, IL (USA), April 19, 2013 – Grünenthal Group is pleased to announce their active participation in the 2013 BIO International Convention, the world’s largest event for the biotechnology industry. The family owned, research driven pharmaceutical company headquartered in Aachen, Germany, will be sharing with the Biotech community exciting developments in the NCE pipeline for pain and inflammation as well as the tamper-resistant formulation technology INTAC®.
16 Apr 2013
Aachen, 17th April 2013 – Grünenthal is pleased with the U.S. Food and Drug Administration’s (FDA) recent decisions regarding abuse deterrent formulations (ADF) and prescription opioids. In its response to a citizen petition by Purdue, generic equivalents to the reformulated abuse deterrent formulation of OxyContin will be required to have similar abuse deterrent properties and undergo specific testing requirements to demonstrate these properties.
06 Mar 2013
Pain Specialist concludes exclusive license, distribution and supply agreement with Ethypharm
Aachen, March 6th 2013. The Grünenthal Group, a global leader in pain therapy with headquarters in Aachen, Germany concludes an exclusive license, distribution and supply agreement with Ethypharm, a French company that is specialized in the development of innovative formulation technologies. The agreement allows the company to commercialize Ethypharm's fentanyl sublingual tablets for the treatment of breakthrough cancer pain in selected European markets.
06 Mar 2013
After three SIP Symposia, this year’s SIP Focus Groups will concentrate on two topics for generating concrete policy instruments and improving chronic pain management in Europe
Brussels/Belgium, 06 March, 2013. This year the European, multi-stakeholder platform “Societal Impact of Pain” (SIP) will organise their annual meeting in the form of SIP 2013 Focus Groups, which will be hosted in the EU Economic & Social Committee and the EU Parliament in Brussels, Belgium on 14-15 May. The aim of the SIP Platform is to raise awareness of the impact of chronic pain, to exchange information and share best-practices across the European Union and to develop and foster policy strategies and activities to improve pain care in Europe.
04 Mar 2013
Aachen, 4th March 2013 – Today, the Grünenthal Group announced the appointment of Yugo Takahashi to assume the position of General Manager, Grunenthal Farmaceutica do Brasil, effective February 27th, 2013. Yugo Takahashi will be based in São Paulo and will report directly to Oscar Ferenczi, Executive Vice President Latin America of the Grünenthal Group.
18 Feb 2013
Oscar Ferenczi, former Region Head of Sandoz Latin America, takes over responsibility for Grünenthal’s Strategic Business Unit (SBU) LATAM.
Aachen, 18 February 2013 – Today, the Grünenthal Group announced the appointment of Oscar Ferenczi to Executive Vice President for the SBU Grünenthal Latin America with immediate effect. In his responsibility he will also take over the task of General Manager Grünenthal S.A. Panama, the regional head office of the company in Latin America, as well as General Manger Grünenthal Latin America, Miami.
12 Feb 2013
Aachen, 12 February 2013 – Today, the Grünenthal Group announced the appointment of Chief Executive Officer, Harald F. Stock, PhD. to the Board of Directors of OvaScienceSM. The life sciences company headquartered in Cambridge, Massachusetts (USA), focuses on the discovery, development and commercialization of new treatments for infertility.